Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/12/2017
SIETES contiene 92148 citas

 
 
 1 a 20 de 14384 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, Hollingworth W, Caldwell DM, Savovic J, Dias S, Salisbury C, Eaton D, Stephens-Boal A, Sofat R. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017;359:j5058. [Ref.ID 102157]
3. Cita con resumen
Miró O, Rosselló X, Gil V, Martín-Sánchez FJ, Llorens P, Herrero-Puente P, Jacob J, Bueno H, Pocock SJ, on behalf of the ICA-SEMES Research Group. Predicting 30-day mortality for patients with acute heart failure in the emergency department: a cohort study. Ann Intern Med 2017;167:698-705. [Ref.ID 102155]
4. Cita con resumen
Maura G, Pariente A, Alla F, Billionnet C. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a french nationwide cohort study. Pharmacoepidemiol Drug Saf 2017;26:1367-77. [Ref.ID 102133]
5. Cita con resumen
Kjerpeseth LJ, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol 2017;73:1417-25. [Ref.ID 102130]
6. Cita con resumen
Fanning L, Ilomäki J, Bell JS, Darzinš P. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. Eur J Clin Pharmacol 2017;73:1427-36. [Ref.ID 102129]
7. Cita con resumen
Wilke T, Groth A, Fuchs A, Pfannkuche M, Maywald U. Persistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large sample of 38,076 German patients. Eur J Clin Pharmacol 2017;73:1437-47. [Ref.ID 102128]
8. Cita con resumen
Anónimo. Fingolimod (Gilenya): nuevas contraindicaciones de uso en pacientes con patología cardiaca subyacente y recomendaciones de revisiones dermatológicas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:6 de noviembre. [Ref.ID 102124]
9. Cita con resumen
Alharbi FF, Souverein PC, de Groot MCH, Blom MT, de Boer A, Klungel OH, Tan HL. The impact of serum potassium-influencing antihypertensive drugs on the risk of out-of-hospital cardiac arrest: a case–control study. Br J Clin Pharmacol 2017;83:2541-8. [Ref.ID 102115]
10. Cita con resumen
Hawkes N. Statin initiation is unrelated to cardiovascular risk score, finds study.. BMJ 2017;359:j4898. [Ref.ID 102110]
11.Tiene citas relacionadas Cita con resumen
Piccini JP, Jones WS. Triple therapy for atrial fibrillation after PCI. N Engl J Med 2017;377:1580-2. [Ref.ID 102100]
12.Tiene citas relacionadas Cita con resumen
Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, ten Berg JM, Steg PG, Hohnloser SH, for the RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513-24. [Ref.ID 102099]
13. Cita con resumen
Ekelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Díaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim J-H, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Bruns NC, Misselwitz F, Chen E, Leong D, Yusuf S, for the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017:5 de octubre. [Ref.ID 102087]
14. Cita con resumen
Ham AC, van Dijk SC, Swart KMA, Enneman AW, van der Zwaluw NL, Brouwer-Brolsma EM, van Schoor NM, Zillikens MC, Lips P, de Groot LCPGM, Hofman A, Witkamp RF, Uitterlinden AG, Stricker BH, van der Velde N. Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis. Br J Clin Pharmacol 2017;83:2292-302. [Ref.ID 102082]
15.Tiene citas relacionadas Cita con resumen
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thompson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J, for the WHI Investigators. Menopausal Hormone therapy and long-term all-cause and cause-specific mortality. The Women’s Health Initiative randomized trials. JAMA 2017;318:927-38. [Ref.ID 102070]
16.Tiene citas relacionadas Cita con resumen
McNeil M. Menopausal hormone therapy. Understanding long-term risks and benefits. JAMA 2017;318:911-3. [Ref.ID 102069]
18. Cita con resumen
Sugiyama T. Osteoporotic fractures associated with dabigatran vs warfarin. JAMA 2017;318:90-1. [Ref.ID 102054]
20.Tiene citas relacionadas Cita con resumen
Gieling EM, van den Ham HA, van Onzenoort H, Bos J, Kramers C, de Boer A, de Vries F, Burden AM. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol 2017;83:1844-59. [Ref.ID 102014]
Seleccionar todas
 
 1 a 20 de 14384 siguiente >>